HRONIČNA RENALNA INSUFICIJENCIJA KOD PACIJENTA NA SUPSTITUCIONOJ TERAPIJI METADONOM
Abstract
Introduction. Opioid addiction is a chronic condition related to different morbidities. The methadone substitution therapy of the opioid addict, combined with social, health, and psychological services is a gold standard of the treatment. All opioids display numerous side effects. Kidney damage in opioid addicts is due to sepsis, rhabdomyolysis, decreased glomerular filtration, hypotension, pulmonary edema, renal lipidosis, or amyloidosis.
Case report. The male patient, 40, on methadone substitution therapy feels weak, sweats excessively. Lab work: potassium 9.87 mmol/L, BUN 18.3 mmol/L, creatinine 268 µmol/L, urea clearance 0,20 ml/s, creatinine clearance 0,81 ml/s, eGFR 23 ml/min/1,73m2, creatine phosphokinase 1180 IU/L, Hgb 79 g/L, Er 2.81x1012/L, C-reactive protein 13.2 µg/mL, Le 7.41x109/L, PCO2 41 mmHg, HCO3 22 mmol/L, and acidosis, pH 7.21. Blood pressure 130/80 mmHg and heart rate 64 bpm, ECG shows prolonged PR interval and high T waves. He was treated with crystalloid iv solutions, 8.4% bicarbonate solutions, diuretics, calcium gluconate, shortacting insulin, antibiotics, and anticoagulants. After therapy, there is an improvement in his potassium levels, diuresis, and ECG. After 24 days of hospital treatment, he was discharged to home care.
Conclusion. Patients on methadone substitution therapy have a higher risk of multiple organ damage. Kidney function is especially at risk. It is of utmost importance to raise awareness among physicians of the danger of rabdomyolysis in these patients. Regular lab checks in patients on methadone substitution therapy can timely detect severe acute and chronic kidney complications and enable timely treatment.
References
Dragan-Saveljić J, Vučetić-Arsić S, Raičević S, Baskot S, et al. Tretman zavisnika od opijata i opioida: Nacionalne smernice za lekare u primarnoj zdravstvenoj zaštiti. Publikacija Ministarstva zdravlja Srbije. April 2010. www.zdravlje.gov.rs
WHO. Global Hepatitis Report 2017. In: Organization W. H., editor, Geneva: World Health Organization; 2017. https://apps.who.int/iris/bitstream/handle/10665/255016/9789?sequence=1
Grebely J, Larney S, Peacock A, Colledge S, Leung J, Hickmanm, et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction. 2019;114(1):150–166. doi:10.1111/add.14393.
Ivanović, N. Razlike u sprovođenju metadonskog programa u evropskim zemljama. Racionalna terapija. 2016;8(2):1523. DOI: 10.5937/racter8-9730
Vučković N, Dickov A, Kovačević M, Simonović P, Saveljić JD, Kovačević M, et al. Supstituciona terapija zavisnika od opijata. Izmena i dopuna nacionalnih smernica. Beograd: Ministarstvo zdravlja Republike Srbije, Republička stručna komisija za prevenciju i kontrolu bolesti zavisnosti. 2012.
Lentine KL, Yuan H, Tuttle-Newhall JE, et al. Quantifying prognostic impact of prescription opioid use before kidney transplantation through linked registry and pharmaceutical claims data. Transplantation 2015; 99(1): 187–196.
Aghabiklooei A, Edalatparvar M, Zamani N, Mostafazadeh B. J Toxicol. Prognostic factors in acute methadone toxicity: a 5-year study. J Toxicol 2014; 2014: 341826.
Mansoor K, Kheetan M, Shahnawaz S, P. Shapiro A, Patton-Tackett E, Dial L, et al. Systematic review of nephrotoxicity of drugs of abuse, 2005–2016. BMC Nephrology (2017) 18:379. DOI 10.1186/s12882-017-0794-0.
Alinejad S, Ghaemi K, Abdollahi M, Mehrpour O. Nephrotoxicity of methadone: a systematic review. Springer Plus. 2016. 9;5(1):2087-2094. doi: 10.1186/s40064-016-3757-1.eCollection 2016.
Kovačević Z, Derić-Jeremić M, Derić D, Ognjanović N, Sazdanović M. Prikaz slučaja - rabdomioliza izazvana metadonom. Engrami 2020; 42(1): 83-91.
Pilgrim JL, McDonough M, Drummer OH. A review of methadone deaths between 2001 and 2005 in Victoria, Australia. Forensic Sci Int 2013; 226(1): 216–222.
McNicol ED, Ferguson MC, Schumann R. Methadone for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2017, Issue 5. Art. No.: CD012499. DOI:10.1002/14651858.CD012499.pub2.
Manchikanti L, Kaye AM, Knežević NN, McAnally H, Slavin K, Trescot AM, et al. Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. Pain Physician. 2017 Feb;20(2S): S3-S92. PMID: 28226332.
Alinejad S, Ghaemi K, Abdollahi M, Mehrpour O. Nephrotoxicity of methadone: a systematic review. Springer Plus. 2016. 9;5(1):2087-2094. doi: 10.1186/s40064-016-3757-1.eCollection 2016.
Dhodi DK, Bhagat SB, Pathak D, Patel SB. Drug-induced nephrotoxicity. Int J Basic Clin Pharmacol 2014; 3(4): 591–597.
Gramenz P, Roberts D, Schrag L. Intraarterial self-injection of methadone tablets into the femoral artery. J Emerg Med 2010; 39(3): 125-127.
Ministarstvo zdravlja Republike Srbije. Nacionalni vodič dobre kliničke prakse za prevenciju, dijagnostikovanje i lečenje hronične bolesti bubrega.
Coluzzi F, Caputi FF, Billeci D, Pastore AL, Candeletti S, Rocco M, et al. Safe Use of Opioids in Chronic Kidney Disease and Hemodialysis Patients: Tips and Tricks for Non-Pain Specialists. Therapeutics and Clinical Risk Management 2020;16:821-837.
Crnić KB, Todorović MM. Recidivantnost kod opijatskih zavisnika na supstitucionoj terapiji buprenorfinom - prikaz slučaja. Hospital Pharmacology - International Multidisciplinary Journal 2017; 4(2): 533-541.
Copyright (c) 2021 Snežana Knežević; Branimir Dugalić, Anđelka Dugalić
![Creative Commons License](http://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Autori zadržavaju autorska prava nad objavljenim člancima, a izdavaču daju neekskluzivno pravo da članak objavi, da u slučaju daljeg korišćenja članka bude naveden kao njegov prvi izdavač, kao i da distribuira članak u svim oblicima i medijima.